Viavi Solutions Inc.
$9.16B- Market cap
- $9.56B
- Debt
- +$244.80M
- Cash
- −$649.80M
Capital structure 98% equity / 2% debt · EV / Revenue 6.03x · EV / EBITDA 74.69x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VIAV stock price vs AMPH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMPH's multiple
Needs AMPH P/S.
Implied fair value · at VIAV's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VIAV FY 2026 (ended Jun 27, 2026) · AMPH FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 6.03x · EV / EBITDA 74.69x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Viavi Solutions Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amphastar Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
0.79x
Net debt / EBITDA
Leverage against operating earnings
-3.30x
1.58x
Cash and equivalents
Liquid reserves on the balance sheet
$649.80M
$282.81M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Broadcom Inc.
VIAV vs AVGO
TEXAS INSTRUMENTS INC
VIAV vs TXN
ANALOG DEVICES INC
VIAV vs ADI
SKYWORKS SOLUTIONS, INC.
VIAV vs SWKS
Qorvo, Inc.
VIAV vs QRVO
Marvell Technology, Inc.
VIAV vs MRVL
BRISTOL MYERS SQUIBB CO
VIAV vs BMY
TEVA PHARMACEUTICAL INDUSTRIES LTD
VIAV vs TEVA
Bausch Health Companies Inc.
VIAV vs BHC
PERRIGO Co plc
VIAV vs PRGO
ANI PHARMACEUTICALS INC
VIAV vs ANIP
$244.80M
$619.71M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.